NCT00005931已完成2 期
A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma
SUGEN2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).
详细描述
Patients are given SU5416 via twice-weekly intravenous infusions in 4-week treatment cycles. Any patient who has not experienced unacceptable toxicity and who is deemed to be responding to the study drug (no evidence of disease progression) is permitted to continue receiving SU5416 in 4-week treatment cycles (up to a maximum of 1 year of therapy) until that patient experiences either unacceptable toxicity or tumor progression, as defined in the protocol.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Are at least 18 years old.
- •Have taken paclitaxel, DaunoXome, or Doxil for KS and they have either not gotten better or could not tolerate treatment therapy.
- •Have 1 of the following symptoms for KS: 5 lesions (sores), generalized KS-related edema (swelling) without sores, or KS-related edema of the arms and legs.
- •Agree to use an effective method of birth control during the study.
排除标准
- •Patients will not be eligible for this study if they:
- •Are pregnant or breast-feeding.
- •Are allergic to Cremophor.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's SarcomaSarcoma, KaposiHIV InfectionsNCT00002226SUGEN30
已完成
2 期
Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected AdultsHIV-1 Infection in AdultsNCT01668043United Biomedical29
终止
2 期
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerColorectal CancerNCT00006001National Cancer Institute (NCI)37
已完成
2 期
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine TherapyPancreatic CancerNCT00372944AstraZeneca70
终止
2 期
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.HIV InfectionsNCT00040157Alexion Pharmaceuticals, Inc.60